A Phase II Trial of Oral Capecitabine in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
OBJECTIVES: I. Determine the response rate and time to treatment failure in patients with
recurrent ovarian epithelial, fallopian tube, or primary peritoneal carcinoma treated with
oral capecitabine. II. Determine the tolerability and safety of this regimen in these
OUTLINE: Patients receive oral capecitabine twice daily for 14 days. Treatment continues
every 3 weeks in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 14-35 patients will be accrued for this study.
Primary Purpose: Treatment
Paul Sabbatini, MD
Memorial Sloan-Kettering Cancer Center
United States: Federal Government
|Memorial Sloan-Kettering Cancer Center||New York, New York 10021|